Company records / oyster-tx.com

Oyster Therapeutics (anteriormente Kesmalea Therapeutics)

Oyster Therapeutics (anteriormente Kesmalea Therapeutics) (oyster-tx.com): no confident changes recorded yet; website history since November 2026. Homepage last checked 11 November 2026.

First recorded website

Observed 11 November 2026

Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.

Oyster Therapeutics is developing a new generation of oral, brain-penetrant protein degraders using its proprietary SELFTAC® platform, initially targeting Alzheimer's disease.

Homepage

Displayed as investors on the website: 4Bio Capital · Lilly · Mission Biocapital · MGB Ventures · Oxford Science Enterprises · Syncona

current websiteHistorical capture not publicly availableLink to first observation

All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

No changes recorded yet. Missing observations do not mean the company has not changed.

Companies in the same space

Other funded startups with the most similar descriptions of what they do. This does not mean they compete directly.

Cite this record

StartupHistory, “Oyster Therapeutics (anteriormente Kesmalea Therapeutics)” company record, https://startuphistory.org/c/oyster-tx.com

Machine-readable: /c/oyster-tx.com.json. How changes are found: method.